Entologi makes third acquisition of the year

Announcing the acquisition, Entologi said the former plc had experienced difficulty attracting shareholder interest over the past few years but retained valuable intellectual property and has an enviable client list within the pharmaceutical sector which forms its core market. Entologi's owners, chairman Neville Buckley and CEO Carl Krajewski, claim that their strategy of organic and acquisitive growth will result in the group, which has assimilated two other acquisitions this year, achieving £60 million turnover within three years. Buckley said: "With 'world class engineering solutions' as our strapline, the acquisition of a company whose ethos is already aligned with ours is ideal. Being part of a bigger Group should allow the RTS team the freedom to concentrate on exploiting our combined technology to bring new products to market." Entologi's management says it believes that since the UK's Victorian engineering glory days, the sector has been overlooked. However, with industry analysts predicting a return to significant growth, a business with engineering excellence at its core operating in various vertical markets should be a seriously profitable proposition. With a client list including the top ten global pharmaceutical companies, RTS is a market leader in compound storage and is becoming a leading supplier in the rapidly expanding biobanking arena. RTS already uses technology and products from two other companies within the Entologi Group, HMK and Specific Environments. RTS Life Science incorporates RTS's specialist robotics and industrial technology group whose research is already central to several of RTS's products, such as its Tube Auditor and its Biobanking product line. A spokesman for the group said Entologi had another two company acquisitions in its sights before March, with one of those being before Christmas.